Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glucocorticoids | 7 | 2014 | 362 | 1.540 |
Why?
|
| Genome-Wide Association Study | 10 | 2023 | 1762 | 0.850 |
Why?
|
| Lymphocytes | 2 | 2013 | 454 | 0.650 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 255 | 0.580 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2023 | 2465 | 0.560 |
Why?
|
| Receptors, Glucocorticoid | 3 | 2014 | 144 | 0.550 |
Why?
|
| Phenotype | 7 | 2023 | 2544 | 0.550 |
Why?
|
| Transcription, Genetic | 4 | 2016 | 1117 | 0.480 |
Why?
|
| Pharmacogenomic Variants | 1 | 2015 | 45 | 0.440 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2015 | 125 | 0.430 |
Why?
|
| Dexamethasone | 3 | 2014 | 312 | 0.420 |
Why?
|
| Mifepristone | 1 | 2014 | 51 | 0.420 |
Why?
|
| Albumins | 1 | 2014 | 123 | 0.420 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2014 | 21 | 0.410 |
Why?
|
| Interleukin-6 | 2 | 2014 | 276 | 0.410 |
Why?
|
| Gene Expression Regulation | 6 | 2019 | 1985 | 0.400 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 202 | 0.390 |
Why?
|
| Transcriptome | 4 | 2013 | 762 | 0.390 |
Why?
|
| Genetic Markers | 1 | 2014 | 469 | 0.380 |
Why?
|
| Paclitaxel | 1 | 2014 | 479 | 0.370 |
Why?
|
| Cell Proliferation | 3 | 2016 | 1741 | 0.360 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2014 | 183 | 0.360 |
Why?
|
| Polymorphism, Genetic | 2 | 2012 | 826 | 0.350 |
Why?
|
| Gene-Environment Interaction | 1 | 2012 | 120 | 0.330 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2015 | 646 | 0.330 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2016 | 208 | 0.300 |
Why?
|
| Blood Proteins | 2 | 2020 | 145 | 0.290 |
Why?
|
| Quantitative Trait Loci | 5 | 2018 | 630 | 0.290 |
Why?
|
| Crohn Disease | 2 | 2015 | 808 | 0.280 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2020 | 2484 | 0.280 |
Why?
|
| Colitis, Ulcerative | 2 | 2015 | 800 | 0.280 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 1275 | 0.270 |
Why?
|
| Asthma | 2 | 2018 | 1039 | 0.250 |
Why?
|
| B-Lymphocytes | 1 | 2011 | 701 | 0.250 |
Why?
|
| Chromosome Mapping | 4 | 2019 | 1052 | 0.250 |
Why?
|
| Calcitriol | 2 | 2016 | 173 | 0.210 |
Why?
|
| Meta-Analysis as Topic | 2 | 2023 | 83 | 0.200 |
Why?
|
| Disease | 1 | 2023 | 92 | 0.180 |
Why?
|
| Humans | 20 | 2023 | 93515 | 0.180 |
Why?
|
| Gene Expression Profiling | 4 | 2018 | 1518 | 0.170 |
Why?
|
| Gene Frequency | 1 | 2023 | 700 | 0.170 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 3110 | 0.160 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2020 | 50 | 0.160 |
Why?
|
| Albuminuria | 1 | 2019 | 51 | 0.150 |
Why?
|
| Proteome | 1 | 2020 | 153 | 0.150 |
Why?
|
| Drug Discovery | 1 | 2018 | 113 | 0.130 |
Why?
|
| Genetic Variation | 2 | 2016 | 1415 | 0.130 |
Why?
|
| Adaptive Immunity | 2 | 2014 | 179 | 0.120 |
Why?
|
| Heredity | 1 | 2015 | 20 | 0.110 |
Why?
|
| Endophenotypes | 1 | 2015 | 19 | 0.110 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 306 | 0.110 |
Why?
|
| Phytohemagglutinins | 1 | 2014 | 19 | 0.110 |
Why?
|
| CD3 Complex | 1 | 2014 | 135 | 0.100 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 88 | 0.100 |
Why?
|
| CD28 Antigens | 1 | 2014 | 94 | 0.100 |
Why?
|
| Databases, Genetic | 1 | 2015 | 282 | 0.100 |
Why?
|
| Genetic Linkage | 1 | 2015 | 613 | 0.100 |
Why?
|
| Drug Resistance | 1 | 2014 | 233 | 0.100 |
Why?
|
| Immunity, Innate | 2 | 2014 | 463 | 0.100 |
Why?
|
| Transcription Factors | 2 | 2012 | 1691 | 0.100 |
Why?
|
| Cells, Cultured | 2 | 2016 | 2850 | 0.100 |
Why?
|
| Lipopolysaccharides | 1 | 2014 | 301 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 691 | 0.090 |
Why?
|
| Lung | 1 | 2019 | 1366 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 754 | 0.090 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2011 | 10 | 0.090 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2011 | 37 | 0.090 |
Why?
|
| Italy | 1 | 2011 | 110 | 0.090 |
Why?
|
| Cell Line, Transformed | 1 | 2011 | 152 | 0.090 |
Why?
|
| Trans-Activators | 1 | 2013 | 439 | 0.080 |
Why?
|
| Nigeria | 1 | 2011 | 162 | 0.080 |
Why?
|
| RNA-Binding Proteins | 1 | 2013 | 306 | 0.080 |
Why?
|
| Transcriptional Activation | 1 | 2011 | 290 | 0.080 |
Why?
|
| Genotype | 1 | 2015 | 1866 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2013 | 353 | 0.080 |
Why?
|
| United Kingdom | 2 | 2023 | 190 | 0.080 |
Why?
|
| NF-kappa B | 1 | 2013 | 408 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2015 | 580 | 0.080 |
Why?
|
| Immediate-Early Proteins | 1 | 2011 | 161 | 0.080 |
Why?
|
| Alleles | 1 | 2013 | 1139 | 0.080 |
Why?
|
| Middle Aged | 7 | 2023 | 27573 | 0.080 |
Why?
|
| Pharmacogenetics | 1 | 2014 | 456 | 0.080 |
Why?
|
| Precision Medicine | 1 | 2014 | 456 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 1338 | 0.070 |
Why?
|
| Young Adult | 3 | 2015 | 6930 | 0.070 |
Why?
|
| Biomarkers | 1 | 2014 | 1910 | 0.070 |
Why?
|
| Risk Factors | 4 | 2019 | 5899 | 0.070 |
Why?
|
| Female | 6 | 2019 | 48702 | 0.060 |
Why?
|
| Genetic Loci | 2 | 2019 | 260 | 0.060 |
Why?
|
| Genomics | 1 | 2011 | 848 | 0.060 |
Why?
|
| Male | 6 | 2019 | 44557 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 2544 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 1775 | 0.050 |
Why?
|
| Adult | 4 | 2018 | 27918 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2015 | 10164 | 0.050 |
Why?
|
| Estonia | 1 | 2023 | 1 | 0.050 |
Why?
|
| Finland | 1 | 2023 | 31 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2018 | 3054 | 0.040 |
Why?
|
| Interferon-Induced Helicase, IFIH1 | 1 | 2018 | 10 | 0.040 |
Why?
|
| Lipase | 1 | 2018 | 21 | 0.040 |
Why?
|
| Creatinine | 1 | 2019 | 293 | 0.040 |
Why?
|
| Genetic Pleiotropy | 1 | 2018 | 29 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2018 | 122 | 0.030 |
Why?
|
| Animals | 2 | 2019 | 28155 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 300 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 7061 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 304 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2018 | 3502 | 0.030 |
Why?
|
| Receptors, Calcitriol | 1 | 2016 | 131 | 0.030 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2016 | 166 | 0.030 |
Why?
|
| Smoking | 1 | 2019 | 648 | 0.030 |
Why?
|
| Aged | 3 | 2019 | 20434 | 0.030 |
Why?
|
| Drosophila melanogaster | 1 | 2019 | 630 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1931 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 1006 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 296 | 0.030 |
Why?
|
| Prostatic Hyperplasia | 1 | 2015 | 95 | 0.030 |
Why?
|
| Electron Transport | 1 | 2013 | 72 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 402 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 711 | 0.020 |
Why?
|
| Vitamins | 1 | 2013 | 85 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2013 | 315 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2015 | 337 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 767 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 1170 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2715 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2018 | 1264 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 1243 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 317 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1534 | 0.020 |
Why?
|
| Cell Line | 1 | 2013 | 2464 | 0.020 |
Why?
|
| United States | 1 | 2015 | 7622 | 0.010 |
Why?
|